Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 27

1 990 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 990
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 990 trials in Auderghem

Open in trial search

A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.

Hypersensitivity+1

Recruiting

A Study Testing Prolonged versus Single Dose Penicillin Challenge in Patients with Suspected Penicillin Allergy Using Amoxicillin

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin Trihydrate
  • Sponsor:Austin Health

A Study of IMVT-1402 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy to Prevent Disease Relapse

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Study of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:DB-1303
  • Sponsor:BioNTech SE

Study of BNT326 alone and with BNT327 in patients with advanced solid tumors: Testing safety and effectiveness of new cancer treatments

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BNT326
  • Sponsor:BioNTech SE

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative+1

Recruiting

Study of MT-501 in patients with active Crohn's Disease or Ulcerative Colitis: A Phase 2 safety and effectiveness trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:MT-201
  • Sponsor:Mirador Therapeutics Inc.

Study of axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study of Apitegromab Treatment in Children Under 2 Years Old with Spinal Muscular Atrophy (SMA)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Apitegromab
  • Sponsor:Scholar Rock Inc.

Asthma

Recruiting

Study of depemokimab to improve airway function in patients with type 2 eosinophilic asthma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.